AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35934637
Drug: Routine pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine pressure injury prevention care and daily visual skin assessment
Trial: 35180125
Drug: Fosgonimeton 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosgonimeton 40 mg in AD subjects (n=7)
Trial: 35180125
Drug: Fosgonimeton (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosgonimeton (various doses) in healthy young males (n=48)
Trial: 35180125
Drug: Fosgonimeton (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosgonimeton (various doses) in healthy elderly subjects (n=29)
Trial: 35180125
Drug: Fosgonimeton (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosgonimeton (various doses)
Trial: 32190990
Drug: Bimonthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bimonthly ranibizumab (0.5 mg intravitreal)
Trial: 32190990
Drug: Treat-and-extend (T&E)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treat-and-extend (T&E) ranibizumab (0.5 mg intravitreal)
Trial: 32190990
Drug: Pro re
RxNorm normalized name: Blistex Pro Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro re nata (PRN) ranibizumab (0.5 mg intravitreal)
Trial: 34078520
Drug: Self-administered cryotherapy
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered cryotherapy
Trial: 34193264
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa officinalis syrup
Trial: 36039762
Drug: MEDI6012 (2-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6012 (2- or 6-dose regimen)
Trial: 36039762
Drug: MEDI6012 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6012 (6 doses)
Trial: 34753423
Drug: SCB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB with mepivacaine 1%, 25-30 ml (n=30)
Trial: 34753423
Drug: SCB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB with ropivacaine 0.5%, 25-30 ml (n=30)
Trial: 35675601
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin initiated after skin incision
Trial: 35675601
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin initiated 0-30 minutes before skin incision
Trial: 35675601
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin initiated more than 30-60 minutes before skin incision
Trial: 35675601
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin initiated more than 60 minutes before skin incision
Trial: 33403734
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil
Trial: 33403734
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil
Trial: 33598874
Drug: FF/UMEC/VI (100/31.25/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI (100/31.25/25 μg, 100/62.5/25 μg, 200/31.25/25 μg, 200/62.5/25 μg)
Trial: 33598874
Drug: FF/VI (100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI (100/25 μg, 200/25 μg)
Trial: 34649396
Drug: Social Intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Social Intelligence Counseling Intervention (eight 1-hour weekly sessions)
Trial: 34653648
Drug: Telepsychiatry group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepsychiatry group (at least 50% of treatments via telemedicine, with at least one face-to-face treatment within six months)
Trial: 34653648
Drug: Face-to-face (FTF)
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face (FTF) group (all treatments conducted FTF, with no telemedicine)
Trial: 32233251
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (10 ml)
Trial: 36387337
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months
Trial: 36387337
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 positive subgroup)
Trial: 36387337
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 negative subgroup)
Trial: 33814391
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy with antioxidant medication
Trial: 32345170
Drug: Investigational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational treatment for RCC/UCC
Trial: 35723686
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone (40 mg loading bolus followed by 40 mg/day for 7 days, then tapering over 20 days)
Trial: 32851257
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone
Trial: 34260808
Drug: Nutraceutical containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts administered over a 12-week period
Trial: 32770246
Drug: Combination Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination Nicotine Replacement Therapy (NRT)
Trial: 35312968
Drug: Sublingual atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual atropine sulfate 1% ophthalmic solution (0.5 mg and 1.0 mg)
Trial: 35312968
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg intravenous (IV) atropine dose
Trial: 35312968
Drug: Sublingual atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual atropine sulfate 1% ophthalmic solution
Trial: 34140765
Drug: Pyrotinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (80 mg single dose on days 1 and 9) co-administered with Itraconazole (200 mg once-daily from days 6 to 22)
Trial: 34140765
Drug: Pyrotinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (80 mg single dose on days 1 and 9)
Trial: 32810739
Drug: MitoQ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ (20 mg, 1 hour pre-exercise, chronic supplementation for 21 days)
Trial: 33859520
Drug: Oral resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol (480 mg per day for 4 days)
Trial: 34181475
Drug: XAV-19 at
RxNorm normalized name: crospovidone (19 MPA.S at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAV-19 at 0.5 mg/kg at day 1 and day 5 (group 1)
Trial: 34181475
Drug: XAV-19 at
RxNorm normalized name: crospovidone (19 MPA.S at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAV-19 at 2 mg/kg at day 1 and day 5 (group 2)
Trial: 34181475
Drug: XAV-19 at
RxNorm normalized name: crospovidone (19 MPA.S at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAV-19 at 2 mg/kg at day 1 (group 3)
Trial: 33153527
Drug: Parent-Child Interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Child Interaction Therapy–Emotion Development (PCIT-ED)
Trial: 33217031
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (group L)
Trial: 35512155
Drug: Standard dosing:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing: 1 g of IV TXA 30 min before skin incision, and 1 g at postoperative 30 min and 3 h.
Trial: 35512155
Drug: Weight-based dosing:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing: 10 mg/kg IV TXA 30 min before skin incision, and 10 mg/kg at postoperative 30 min and 3 h.
Trial: 35512155
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (standard and weight-based dosing of IV TXA).
Trial: 35758436
Drug: Neurological Speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated about a month after stroke
Trial: 35758436
Drug: Neurological Speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated more than 6 months after stroke (late therapy)
Trial: 34037294
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for a given vaccine
Trial: 32089848
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention in social insurance medicine
Trial: 32139090
Drug: BSC-pre (halamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSC-pre (halamine antimicrobial curtains sprayed twice weekly with sodium hypochlorite)
Trial: 33468148
Drug: Foot massage
RxNorm normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot massage treatment (10-min daily for four weeks using sweet almond oil)
Trial: 33468148
Drug: Foot massage
RxNorm normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot massage treatment
Trial: 33468148
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no foot massage treatment)
Trial: 35666314
Drug: OPERA® dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPERA® dietary supplement (α‐Lipoic acid, Boswellia serrata, Methylsulfonylmethane, and Bromelain) taken once a day for six months (T0 to T3)
Trial: 35666314
Drug: OPERA® dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPERA® dietary supplement
Trial: 32926462
Drug: Baricitinib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (4 mg)
Trial: 37323710
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard in-hospital treatment)
Trial: 33445146
Drug: CT (Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (Concurrent Training)
Trial: 33445146
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + EL (Concurrent Training + Eurycoma longifolia)
Trial: 32063157
Drug: Nebulised normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised normal saline administered hourly
Trial: 34323341
Drug: Modified WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified WHO cholera solution
Trial: 34955173
Drug: Vaginal Stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Stretching with Photobiomodulation Therapy (PBMT)
Trial: 32620210
Drug: GC-avelumab (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC-avelumab (gemcitabine 1000 mg/m2 on days 1 and 8, Cisplatin 70 mg/m2 on day 1, plus Avelumab 10 mg/kg every 3 weeks)
Trial: 32620210
Drug: GC (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC (gemcitabine 1000 mg/m2 on days 1 and 8, Cisplatin 70 mg/m2 on day 1)
Trial: 36137654
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (preferred by interventional neuroradiologists)
Trial: 35152197
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with induction chemotherapy (Cisplatin 75 mg/m2 and Paclitaxel 175 mg/m2 every 21 days) followed by concurrent chemoradiotherapy (66Gy in 33 fractions for 6.5 weeks)
Trial: 35152197
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (Cisplatin 40 mg/m2 intravenous during chest radiotherapy of 66Gy in 33 fractions for 6.5 weeks)
Trial: 35063882
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy alone
Trial: 32881641
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy, with anti-SARS-CoV-2 titers of >1:640 to >1:1000, dosage and duration not specified.
Trial: 32881641
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy, details on dosage and duration not specified.
Trial: 32915939
Drug: Tretinoin lotion
RxNorm normalized name: tretinoin Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin lotion 0.05%
Trial: 35638317
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg daily for 18 weeks)
Trial: 38770686
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or standard treatment not specified)
Trial: 35093946
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of Rosuvastatin in addition to SSRIs therapy
Trial: 35093946
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to SSRIs therapy
Trial: 35093946
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of Rosuvastatin
Trial: 34367303
Drug: Compound Lidocaine
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Lidocaine Cream (CLC)
Trial: 36079732
Drug: Supplement containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement containing Sambucus nigra, zinc, tyndallized Lactobacillus acidophilus (HA122), arabinogalactans, vitamin D, vitamin E, and vitamin C for 30 days
Trial: 33713211
Drug: New-Generation Drug-Eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New-Generation Drug-Eluting Stents (DES)
Trial: 39593225
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily routine (control group)
Trial: 34147344
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicines (IH)
Trial: 32925621
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (mifepristone and misoprostol)
Trial: 32925621
Drug: Monotherapy (misoprostol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (misoprostol alone)
Trial: 32073619
Drug: ASP‐p iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP‐p iron absorption
Trial: 33613521
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) as adjunct therapy during the first two months of anti-TB treatment
Trial: 35329107
Drug: Synbiotic (Gasteel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic (Gasteel Plus®) administered for 30 days
Trial: 35329107
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 30 days
Trial: 33038950
Drug: Immediate intravenous
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate intravenous bolus of 10% dextrose at 5 mL/kg followed by a 24-h maintenance infusion of 10% dextrose at 100 mL/kg for the first 10 kg of bodyweight, 50 mL/kg for the next 10 kg, and 20 mL/kg for each subsequent kg of bodyweight.
Trial: 36155131
Drug: Reduced-dose glucocorticoid
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose glucocorticoid regimen
Trial: 36155131
Drug: Standard-dose glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose glucocorticoid regimen
Trial: 34010183
Drug: ACEI/ARB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB treatment
Trial: 38319842
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg/day
Trial: 32062173
Drug: High-dose TxA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TxA (30 mg/kg bolus, 16 mg/kg/h maintenance, 2 mg/kg pump prime)
Trial: 32062173
Drug: Low-dose TxA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose TxA (10 mg/kg bolus, 2 mg/kg/h maintenance, 1 mg/kg pump prime)
Trial: 32062173
Drug: High-dose TxA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TxA
Trial: 32062173
Drug: Low-dose TxA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose TxA
Trial: 33332190
Drug: Subsequent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapy (both groups)
Trial: 33332190
Drug: Subsequent targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent targeted therapy
Trial: 33479925
Drug: Counseling on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling on hypoglycemia treatment or avoidance of driving
Trial: 36137638
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) and prednisolone
Trial: 36137638
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human albumin (5%) and placebo tablets
Trial: 32005604
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group received a head turban, sleeping socks, a heated blanket, a Bair Hugger for forced-air warming, and a Mega Acer kit for warming intravenous fluid.
Trial: 32564571
Drug: Ticagrelor 45
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 45 mg bid
Trial: 33150481
Drug: miR-367 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: miR-367 treatment in erythrocyte lysate-treated microglia
Trial: 33100326
Drug: HDL increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL increase (1 SD = 12.26 mg/dL)
Trial: 33100326
Drug: TG increase
RxNorm normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG increase (1 SD = 112.33 mg/dL)
Trial: 33875433
Drug: NTM-1632 (0.033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1632 (0.033 mg/kg)
Trial: 33875433
Drug: NTM-1632 (0.165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1632 (0.165 mg/kg)
Trial: 33875433
Drug: NTM-1632 (0.330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1632 (0.330 mg/kg)
Trial: 33568226
Drug: Encapsulated iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated iodine complex of 200 mg (arm A)
Trial: 33568226
Drug: Iodine complex
RxNorm normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine complex syrup form 40 ml (arm B)
Trial: 33568226
Drug: Iodine complex
RxNorm normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine complex throat spray of 2 puffs (arm C)
Trial: 33568226
Drug: Empty capsule
RxNorm normalized name: Empty Capsule Size 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty capsule (arm D) as placebo
Trial: 35445723
Drug: Pixantrone 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixantrone 180 mg/m2 every 3 weeks (group A)
Trial: 35445723
Drug: Pixantrone 85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixantrone 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B)
Trial: 34499820
Drug: Albuterol nebulized
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol nebulized with 3% hypertonic saline (HSS)
Trial: 34499820
Drug: Albuterol nebulized
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol nebulized with normal saline solution (NSS)
Trial: 36104128
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of LC-Plasma-containing capsule, 200 mg/day, for 14 days